The robustness of the HbF phenotype upon NFIX knockdown and the potential tractability of targeting NFIX by genetic engineering approaches make it an important new target that could yield a therapeutic benefit to hemoglobinopathy patients. This evidence concerns the gene NFIX and hemoglobinopathy.